CFTR and cystic fibrosis: Human nasal epithelial (HNE) cells homozygous for G85E/G85E did not respond to VX-661 but responded to the second-generation correctors, i.e., VX-445 are currently available to patients with CF in a form that also includes the CFTR potentiator, VX-770; this threesome is termed as “TRIKAFTATM.” Similar findings have been described in the studies of the R560K and R560T CFTR variants, and in a recent study, these mutants were not sensitive to recently developed correctors.